The RET proto-oncogene encodes two isoforms of a receptor type tyrosine kinase which plays a role in neural crest and kidney development. Distinct germ-line mutations of RET have been associated with the inherited cancer syndromes MEN2A, MEN2B and FMTC as well as with the congenital disorder Hirschsprung disease (HSCR), whereas somatic rearrangements (RET/PTCs) have been frequently detected in the papillary thyroid carcinoma. Despite these ®ndings, suggesting a relevant role for RET product in development and neoplastic processes, little is known about the signalling triggered by this receptor. In this study, we have demonstrated that the transducing adaptor molecule Shc is recruited and activated by both Ret isoforms and by the rearranged cytoplasmatic Ret/ptc2 oncoproteins as well as by the membrane bound receptor activated by MEN2A or by MEN2B associated mutations. Moreover, our analysis has identi®ed the Ret tyrosine residue and the Shc domains involved in the interaction. In fact, here we show that both the phosphotyrosine binding domains of Shc, PTB and SH2, interact with Ret/ptc2 in vitro. However, PTB domain binds 20 folds higher amount of Ret/ptc2 than SH2. The putative binding site for either SH2 and PTB domains has been identi®ed as Tyr586 of Ret/ptc2 (Tyr1062 on proto-Ret). In keeping with this ®nding, by using RET/PTC2-Y586F mutant, we have demonstrated that this tyrosine residue, the last amino acid but one before the divergence of the two Ret isoforms, is the docking site for Shc.
Introduction
Proto-RET gene encodes two isoforms of a receptor type tyrosine kinase (RTK) (Takahashi et al., 1988; Tahira et al., 1990) . Only very recently a Ret ligand has been identi®ed as the glial derived neurotrophic factor (GDNF) (Trupp et al., 1996; Durbec et al., 1996) . Several studies also involving transgenic mice have demonstrated a critical function for this receptor in kidney and enteric nervous system development (Schuchardt et al., 1994; Pachnis et al., 1993) . Alterations of RET gene have been found associated with ®ve dierent diseases. In fact, distinct germ-line mutations of proto-RET have been identi®ed in the inherited cancer syndromes Multiple Endocrine Neoplasia (MEN) type 2A and 2B and Familial Medullary Thyroid Carcinoma (FMTC) as well as in a congenital malformation, the Hirschsprung disease (HSCR) (reviewed in van Heyningen, 1994 and see references herein). All MEN2A mutations involve cysteine residues present in the extracellular domain of proto-RET, whereas a single point mutation in the TK domain, changing the methionine 918 to threonine, has been found in almost all cases of MEN2B (reviewed in Ponder, 1995 and references herein). On the contrary, somatic rearrangements of RET, generating RET/PTC oncogenes, have been detected in about 35% of surgical specimens from papillary histotype of thyroid carcinomas . RET/PTCs encode fusion proteins in which the tyrosine kinase (TK) and the C-terminal domains of RET are fused to dierent donor genes (Grieco et al., 1990; Bongarzone et al., 1993 Bongarzone et al., , 1994 . All the donor genes, being constitutively expressed in all tissues, are responsible for the ectopic expression of the oncogenes in thyroid cells and, as suggested by sequence analysis and coimmunoprecipitation experiments, their products are endowed with a constitutive dimerization capability, which is then conferred to the chimeric proteins (Bongarzone et al., 1993; . As a consequence, the Ret/ptc oncoproteins are constitutively phosphorylated on tyrosine and display a constitutive tyrosine kinase activity (Lanzi et al., 1992; Borrello et al., 1994) . In addition, we have recently demonstrated that Ret/ptc proteins activate the signal transducer PLCg , as do dierent RTKs triggered by the respective ligands.
By transfection assays, RET/PTCs transform NIH3T3 cells and dierentiate the phechromocytoma cell line PC12 (Grieco et al., 1990; Bongarzone et al., 1993 Bongarzone et al., , 1994 Pasini et al., 1995) . Proto-RET genes, activated by point mutations associated with MEN2A or MEN2B, are also able to transform NIH3T3 and to induce dierentiation of PC12 cells .
Shc is a highly conserved gene, isolated as an SH2-containing protein . It encodes three overlapping proteins of 46, 52 and 66 kDa, that share three distinct domains: a single SH2 domain in the C-terminal portion of the protein; a glycine-and proline-rich region containing a tyrosine phosphorylation site at position 317 responsible for binding the adapter protein Grb2, and the PTB domain, a newly recognized phospho-tyrosine-binding domain unrelated to SH2 domain (Blaikie et al., 1994; Kavanaugh and Williams, 1994) . Shc proteins are ubiquitously expressed and are involved in the signalling pathways triggered by dierent classes of proteins. Several tyrosine kinase receptors Yokote et al., 1994; Segatto et al., 1993; Giorgetti et al., 1994; Vainikka et al., 1994; Borrello et al., 1994; Stephens et al., 1994) as well as non-receptor kinase such as Src, Fps (McGlade et al., 1992) and Lck (Baldari et al., 1995) and surface receptors without intrinsic TK activity (e.g. interleukin receptors, the B-cell antigen receptor and the erythropoietin receptor) are all able to interact with Shc (Damen et al., 1993; Matsuguchi et al., 1994 and references herein) . Shc has also been demonstrated to bind to middle T antigen of Polyoma virus and is involved in middle T antigeninduced oncogenic transformation (Dilworth et al., 1993) . Upon phosphorylation, Shc binds to the Grb2-Sos complex leading to the activation of the Ras signaling pathway (Lowenstein et al., 1992) .
Recently, it has been reported that the direct interactions of Shc with a number of TK receptor such as IR (Gustafson et al., 1995) , TRKA (Dikic et al., 1995) , EGFR and ErbB-3 (Prigent et al., 1995) are primarily mediated by its PTB domain. The PTB domain, at variance with all the SH2 domains, interacts with sequences amino-terminal to the phosphotyrosine, speci®cally recognizing NXXpY motif, where p indicates phosphorylation (Kavanaugh and Williams, 1994; Trub et al., 1995) .
We have previously demonstrated that the chimeric oncogenic proteins Ret/ptc1 and Ret/ptc2 activate Shc proteins. In fact, in cells expressing Ret/ptc oncoproteins, Shc is constitutively phosphorylated and coimmunoprecipitates with Ret/ptc oncoproteins and with Grb2 .
A number of studies have been performed in the last few years in order to identify speci®c phosphotyrosine residues in TK receptors as major or unique binding sites for each one of the known SH2 containing proteins (Pawson and Schlessinger, 1993) . In the case of Ret, the lack of ligand has so far hampered the analysis of its signal transduction pathway that is relevant for the comprehension of the molecular basis of the dierent Ret-associated diseases. However, it is possible to study the signaling of Ret using the Ret oncogenic forms, derived from the dierent diseases, all displaying a constitutively activated tyrosine kinase.
In this report, we demonstrate that the transducing molecule Shc is recruited and activated by all the activated forms of Ret: the membrane bound receptor activated by MEN2B or MEN2A associated mutations, as well as the rearranged cytoplasmic Ret/ptc2 oncoproteins but not the unstimulated proto-Ret product. Moreover, by in vitro inhibition experiments using synthetic phosphopeptides modeled on Ret cytoplasmic amino acidic sequence and the SH2 and PTB Shc domains, we have identi®ed the putative docking sites for Shc on Ret C-terminal. By sitedirected mutagenesis, we have demonstrated that a Ret/ptc2-Y586F (Y-to-F change at position 586) mutant oncoprotein, while maintaining its TK activity, completely loses its ability to coimmunoprecipitate with Shc transducer protein.
Results
In NIH3T3 cell lines expressing dierent oncogenic forms of Ret, Shc is tyrosine phosphorylated and binds
Ret oncoproteins
We have previously demonstrated that Shc is constitutively activated in cells expressing the Ret oncoproteins Ret/ptc1 and Ret/ptc2 Pelicci et al., 1995) . Here we show in Figure 1 that Shc proteins are tyrosine phosphorylated in NIH3T3 cell lines expressing either isoforms p76 or p81 encoded by the chimeric oncogene RET/PTC2 (lane PTC2iso9 and PTC2iso51 of panel a), in NIH3T3 cells expressing Ret-C634R protein, a MEN2A-associated Ret mutant, and in a cell line expressing Ret-M918T, the MEN2B-associated Ret mutant (lane Ret2A and Ret2B of panel d). In addition, the same panels show that a signi®cant fraction of all the Ret oncoproteins coimmunoprecipitate with Shc. On the contrary, untransfected NIH3T3 cells and an NIH3T3 cell line expressing the wild type unstimulated proto-Ret product show a very low level of phosphorylated Shc proteins (lanes NIH and Retwt of panel d). All the cell lines in Figure 1 are representative of a number of cell lines derived from dierent NIH3T3 transfection experiments (Bongarzone et al., 1993; Borrello et al., 1995) and are designated according to the name of the expressed Ret protein. Figure 1b, c,e and f show Shc and Ret expression on the analysed cell lines. All the oncoproteins, but not proto-Ret product, are constitutively phosphorylated on tyrosine (data not shown, see also Borrello et al., 1995 Borrello et al., , 1996 .
We have previously shown that the SH2 domain of Shc binds in vitro Ret/ptc oncoproteins . To investigate whether both the phosphotyrosine-binding domains of Shc, SH2 and PTB domains, could directly bind Ret oncoproteins, an in vitro binding experiment was performed using the Gst-fused SH2 or PTB proteins and a Ret/ptc2 protein extract pretreated with SDS at 1008C to dissociate preexisting protein-protein interactions. The results are shown in Figure 2a : both the Shc domains are still able to bind Ret/ptc2 after the treatment, thus demonstrating that the binding could be direct. To control our experimental conditions, we used in the same experiment Gst-Grb2 and an extract containing activated PDGF receptor, known to interact through Syp and we have con®rmed that this binding is not direct (Figure 2a , last panel).
To estimate the relative anities of the SH2 and PTB Shc domains for Ret, binding experiments were performed in the presence of equal amount of the two domains and increasing amounts of the Ret/ ptc2-containing extract. As shown in Figure 2b , the PTB domain appears to bind about 20 times more Ret/ptc2 protein than the SH2 domain, as estimated by PhosphorImager analysis from three independent experiments. In addition, we have estimated that about 15 ± 20% of the Ret oncoproteins immunoprecipitated with anti-Ret antiserum binds PTB in vitro, with no dierence between the two Ret isoforms, whereas 0.5 ± 1% Ret oncoprotein binds SH2 domain.
Identi®cation of putative docking sites for Shc
To determine the potential Shc binding sites for either domains on Ret protein, a series of synthetic tyrosine phosphorylated decapeptides, corresponding to all the tyrosine residues in the tyrosine kinase domain and in the C-terminal region of Ret, were used (Table 1A) . When 100 mM of each of these peptides were examined for their ability to prevent the in vitro association between the autophosphorylated Ret/ptc2 oncoproteins and the PTB domain fused to Gst, only peptides pY586(iso9) and pY586(iso51) had a slight but consistent eect (data not shown). These peptides encompass the Tyr586 of Ret/ptc2 (Tyr1062 of protoRet) in the two Ret isoforms; in fact this tyrosine is the last amino acid but one before the divergence of the two isoforms (Takahashi et al., 1988 , see also peptide sequence in Figure 5 ). The sequence of both peptides is in agreement with the consensus sequence for binding to the PTB, NXXpY (Kavanaugh and Williams, 1994) . However, since the binding sequence of PTB domain lays in the sequence amino-terminal to pTyr, and the amino acid in 75 position is required for an high anity binding (Trub et al., 1995) , a new phosphopeptide, 76pY586+1, was synthesized, displaying a sequence common to both the isoforms (Table 1B) . As shown in Figure 3a , 76pY586+1 peptide, but not its unphosphorylated version, signi®cantly inhibits the binding between Ret/ptc2 and the PTB domain. The 76pY586+1 phosphopep-
PTC2iso51 PTC2iso51 tide shows, however, a lower competing activity, estimated about one tenth, than pY(MT) ( Table 1B, Zhou et al., 1996) , a peptide corresponding to the sequence 76pY+1 around the docking site of middle T antigen of Polyoma virus for Shc PTB (Figure 3a last panel). The same series of phosphopeptides listed in Table  1A was used to inhibit the binding between Ret/ptc2 and the SH2 domain of Shc fused to Gst. As shown in Figure 3b , two phosphopeptides, pY539 and pY586(iso9) were able to prevent in vitro association between autophosphorylated Ret/ptc2 oncoproteins and Shc SH2 domain, while pY586(iso51) showed a minor inhibiting eect. All the other Ret peptides, listed in Table 1A , have no inhibiting eect (data not shown).
In vitro phosphorylation of Ret synthetic peptides Y586 by Ret/ptc2
To determine whether Tyr586 of Ret/ptc2 could be phosphorylated by Ret kinase, the unphosphorylated decapeptides 74Y586(iso9)+5 and 74Y586(iso51)+5 were tested as substrates in an in vitro kinase reaction using Ret/ptc2 (Figure 4 ). In previous works 74pY+5 peptides were demonstrated to be good substrates in vitro for PDGFR and Ret kinases (Turck and Edenson, 1994; Borrello et al., 1996) . The products of the immunokinase reaction on Y586 peptides, partially puri®ed by reverse-phase HPLC to eliminate ATP, were subjected to TLC followed by autoradiography. As shown in Figure 4 , spots comigrating with the respective cold phosphorylated peptides, used as In vitro binding of Ret/ptc2 oncoproteins to SH2 and PTB domains of Shc. Western blot analysis with anti-Ret or anti-PDGFR antisera using protein extracts from NIH3T3 cell line expressing Ret/ptc2 oncoprotein (PTC2), or from NIH3T3 treated 15' with 50 ng/ml PDGF (NIH+PDGF), in a binding experiment using 10 mg of Sepharose-bound Gst-fusion protein (BP) bearing the indicated domains (SH2 or PTB from Shc and SH2 from Grb2) or the Sepharose-bound Gst (Gst). In (a) 1 mg amount of protein extract in PLC-LB buer was used. The samples were left untreated (lanes7) or boiled in the presence of 1% SDS (lanes 1008C+SDS) before binding 0.3 mg of the same cell extract was immunoprecipitated (IP) with anti-Ret antiserum. Immunoreactive bands were visualized using 125 I-labeled protein A. In (b) 0.5, 1, 2 or 3 mg of Ret/ptc2 expressing protein extract was used. Immunoreactive bands were visualized using peroxidase conjugate secondary antibodies and ECL detection reagents. Arrowheads indicate Ret/ptc2 protein, arrow indicates PDGF receptor references, were present when both the Y586 peptides modeled on Ret/ptc2 either short or long isoform sequences, were used.
Construction of RET/PTC2-Y586F mutant
Because of its ability to bind in vitro both the phosphotyrosine binding domains of Shc, Tyr586 was chosen as the target for mutagenesis to eliminate the putative docking site for Shc in the Ret/ptc2 oncoprotein. Regarding the second putative docking site, Tyr539, we had already demonstrated that a RET/PTC2-Y539F mutant is still able to activate Shc .
The Tyr586?Phe mutation (Y586F) was introduced by site-directed mutagenesis in the RET/PTC2 cDNA encoding the short isoform (Figure 5a and see Materials and methods). A full-length RET/PTC2-Y586F cDNA clone was sequenced in its entirety and was demonstrated to dier from the RET/PTC2-wt only for the introduced missense mutation (data not shown). The RET/PTC2-Y586F was then cloned in pRC-CMV eukaryotic expression vector, carrying the neomycin resistance gene. The pRC-CMV construct and the corresponding construct containing RET/ PTC2-wt were transiently expressed in COS7 cells in order to verify the synthesis of the correctly sized (76 kDa) protein and to compare the biochemical characteristics of the two proteins.
As shown in the left panel of Figure 5b , both constructs express the expected Ret/ptc2 protein reacting with anti-Ret antiserum, while untransfected COS7 cells fail to reveal anti-Ret reactive bands. Wt and mutant Ret proteins display comparable steady state tyrosine phosphorylation level (Figure 5b, right panel) . Moreover, analysed by in vitro immunokinase assay, wt and mutant proteins showed comparable autophosphorylation and substrate-phosphorylation activities on MBP (Figure 5c ). An additional band of slightly higher molecular weight was also variably present ( Figure 5b ) in anti-Ret immunoprecipitates because of translation starting from the ATG present in the pRC-CMV vector 6 bp upstream of the cloning site and in frame with the RET/PTC2 sequence. This band was absent when pMAMNeoblue vector was used and was previously shown not to aect on the , as control, or on sepharose-bound Gst-fused proteins (BP) using 1 mg of cell extract from NIH3T3 cell line expressing Ret/ptc2, 10 mg of the indicated Gst-fusion protein and 100 mM of unphosphorylated (Y) or tyrosine-phosphorylated (pY) synthetic peptides. pY586 indicates the 76pY586+1 phosphopeptide that displays a sequence commmon to both the isoforms. pY586(9) and pY586(51) indicate the isoform-speci®c 74pY586+5 phosphopeptides (see Table 1 ). Figure 4 In vitro phosphorylation of Y586 containing decapeptides by Ret/ptc2 tyrosine kinase. An in vitro kinase reaction was carried out with immobilized Ret/ptc2 oncoprotein to phosphorylate the synthetic decapeptides Y586iso9 (a) and Y586iso51 (b). The peptide containing fractions, derived from the kinase reaction partially puri®ed by HPLC, stopped immediately after the addition of the peptide (t o ) or subjected to 60' of kinase reaction (t 60 ) were runned on TLC. The same plate was stained with ninhydrin to reveal the reference cold phosphorylated peptides (lanes pY586(iso9) and pY586(iso51), indicated by arrowheads); unreacted ATP is indicated results of the comparison between RET/PTC2-wt and other RET/PTC2 mutants .
RET/PTC2-Y586F mutant is not able to interact with Shc proteins
To analyse the ability of Ret/ptc2-Y586F mutant to bind and activate Shc proteins, COS7 cells were transfected with wt and mutant Ret/ptc2. As controls, COS7 cells, either untransfected or transfected with Ret/ptc2-Y539F, or with the kinase negative mutant Ret/ptc2-K282R were used. Ret/ptc2-K282R was obtained by site-directed mutagenesis and cloned in the pRC-CMV vector (data not shown). According to studies on other TK receptors, replacement of the corresponding lysine residue is predicted to inactivate the RET kinase by disrupting the ATP binding site (Chen et al., 1987) . This Ret/ptc2 mutant, obtained by in vitro mutagenesis and cloned on pRC-CMV vector, was in fact demonstrated unable to autophosphorylate and to phosphorylate the exogenous substrate MBP (data not shown). Since even after 40 h serum starvation, untransfected COS7 cells showed phosphorylated Shc proteins, we could not use this test to analyse the ability of the various RET/PTC2 mutants to activate Shc by tyrosine phosphorylation. However, we could demonstrate that, whereas Ret/ptc2-Y539F, like Ret/ptc2-wt, was still able to coimmunoprecipitate with Shc proteins, both Ret/ptc2-Y586F, which lacks the putative docking site for Shc, and Ret/ptc2-K282R, which is devoid of tyrosine kinase activity, were not (Figure 6a ), clearly indicating that the presence of the phosphorylated Tyr586 is essential for the interaction between Ret and Shc. Figure 6b , c and d are control Western blot analyses, showing that all the constructs were similarly expressed ( Figure 6c ) and that the Y539F and Y586F, but not the K282R mutants display tyrosine phosphorylation similar to the wt (Figure 6d ). The in vitro binding ability of wt and Y586F mutant Ret/ptc2 for the two separate domains of Shc was also analysed. The Y586F mutation clearly abolished the ability of Ret/ptc2 to bind both the PTB and the SH2 domain of Shc (data not shown).
Discussion
Distinct RET gene mutations are associated with several forms of human diseases. Both the point mutated RET genes found in multiple endocrine neoplasias MEN2A and MEN2B, and somatically rearranged RET gene of papillary thyroid carcinoma (RET/PTCs), encode oncogenic forms of Ret, showing a constitutive activation of their tyrosine kinase activity and, upon transfection, the ability to transform NIH3T3 cells and to dierentiate PC12 pheochromocytoma cell line Borrello et al., 1995; Pierotti et al., 1996) . We have previously shown that the transducing molecule Shc is constitutively activated by Ret/ptcs oncoproteins Pelicci et al., 1995) . In this paper, we have analysed Shc activation in stable cell lines expressing the Ret gene carrying a MEN2A (Ret-C634R) or the MEN2B mutation (Ret-M918T) and we have demonstrated that all Ret oncoproteins are able to recruit and activate Shc. Given that Ret/ptc oncoproteins localize in the cytoplasm, whereas Ret-C634R and Ret-M918T maintain the transmembrane localization as proto-Ret, these ®ndings indicate that, irrespectively of the subcellular localizations, the cytoplasmic domain of Ret is suited to recruit Shc. In addition, although the M?T mutation associated with MEN2B, as well as the M?T mutation at the corresponding amino acid in EGFR, was demonstrated responsible for changing the substrate speci®city of the kinase (Songyang et al., 1995; Pandit et al., 1996) , Shc appears a common substrate for wild type and MEN2B Ret kinase. This ®nding is in agreement with the evidence that both the receptor-type tyrosine kinases, harboring a methionine, and the Src-like tyrosine kinases, harboring a threonine in the corresponding position (Hanks et al., 1994) , are able to activate Shc (e.g. Pelicci et al., 1992; McGlade et al., 1992) .
Moreover, we have analysed the ability of either Ret isoforms, separately expressed, to activate Shc. Ret gene codes for two isoforms diering in their Cterminal (Tahira et al., 1990) , the longest isoform displaying two tyrosines absent in the short one. Interestingly, a common tyrosine, the last amino acid but one before the divergence of the two isoforms (Tyr586 on Ret/ptc2), could have dierent SH2 domain-speci®city because of the dierence in the two isoforms C-terminal amino acid sequence. However, by using cell lines expressing Ret/ptc2-iso9 or Ret/ptc2-iso51 only, we have demonstrated a comparable Shc recruitment, thus suggesting that the major docking site for Shc lays in the aminoacidic sequence common to both isoforms.
Since Shc proteins harbor a classical SH2 domain and a structurally unrelated domain, recently characterized and designated PTB Kavanaugh and Williams, 1994) , which bind phosphotyrosine with high anity, the ability of Ret/ptc2 to directly bind these domains was tested. We have shown that both PTB and SH2 Shc domains are able to directly bind in vitro Ret/ptc2, although PTB shows a 20 fold higher anity, suggesting that it could be the major or the unique binding site for Ret. By in vitro binding inhibition experiments, we have determined the putative docking site for both SH2 and PTB domains.
Using a series of phosphorylated decapeptides, corresponding to all the cytoplasmatic tyrosine residues of Ret, we have shown that three peptides, one encompassing Tyr539 and two Tyr586, with its isoform 9 or isoform 51 environments, inhibited the binding between Ret/ptc2 and SH2(Shc). Whereas the role of Tyr586 (Tyr1062 for proto-Ret) was not previously investigated, we had previously shown, using stable cell lines expressing Ret/ptc2-Y539F, that the presence of Tyr539, the docking site for PLCg, is not necessary to activate Shc , thus ruling out that Tyr539 (Tyr1015 for proto-Ret) could have a crucial role as docking site for Shc.
The quanti®cation of the binding experiments showed, however, that less than 1% of the Ret/ptc2 present in the extract was able to bind in vitro the Gst-SH2 protein, whereas about 20% of the protein interacts with Gst-PTB fusion protein in the same experimental conditions. The candidate docking site for PTB domain was again Tyr586. In fact, the 74pY586+5 phosphopeptide was the only one able to inhibit the binding between Ret/ptc2 and PTB(Shc) and, in addition, the amino acid sequence around this tyrosine residue was in good agreement with the consensus for the PTB domain. The sequence NXXpY was strictly required for PTB binding (Kavanaugh and Williams, 1994; Van der Geer et al., 1996; Laminet et al., 1996) and Tyr586 was the only one cytoplasmic Ret tyrosine with Asn in 73 position. Although the majority of the identi®ed PTB docking sites share the sequence NPXpY (Zhou et al., 1996) , the presence of Pro in 72, absent in 72 position of Tyr 586, was demonstrated not essential (Dikic et al., 1995) . In addition, PTB domain, at variance with SH2 domains, needs at least ®ve residues N-terminal to pTyr for its binding, with a strong requirement for a non-polar wt  wt  wt  wt  Y586F  Y586F  Y586F  Y586F  Y539F  Y539F  Y539F  Y539F  K282R  K282R  K282R isoleucine residue in 75 position. A 76pY586+1 phosphopeptide, corresponding to the last common Ret amino acids and thus representative of both Ret isoforms, was used to block Ret/ptc2-PTB(Shc) binding. The peptide was indeed eective although about tenfold less ecient than the 76pY+1 peptide corresponding to the PTB docking site of polyoma virus middle T antigen (Laminet et al., 1996) . Studies of Zhou et al. (1996) , using NMR and surface plasmon resonance techniques with phosphorylated peptides, demonstrated that binding anity of PTB(Shc) domain for its docking sites (K d 0.03 ± 5.3 mM) is generally higher than that of SH2(Shc) domain for its own sites (K d 50 ± 130 mM) and, in particular, the K d for PTB and middle T was 0.14. These data are in keeping with those here reported showing that Ret/ptc2 binds PTB domain one order of magnitude more than SH2 domain. Moreover, following similar experiments using Trk oncoproteins , we found that the latter bind at least 100 times more PTB than SH2 domain of Shc (data not shown), according with the results of Dikic et al. (1995) obtained with activated proto-Trk receptor.
In conclusion, we have de®ned a major role for the PTB domain and a minor role, if any, for the SH2 domain in driving Ret-Shc interaction. Since the same tyrosine residue is the putative docking site for both PTB and SH2 domains, Shc could interact with two Ret molecules by using both domains, thus playing a role in stabilizing dimers' formation, as previously hypothesized for EGFR and ERBB3 (Prigent et al., 1995) .
At variance with most of TK receptors showing multiple docking sites for Shc Segatto et al., 1993) , we have demonstrated that a unique tyrosine residue in the C-terminal of Ret is responsible for binding to Shc. In fact, the Ret/ptc2-Y586F mutant was not only unable to bind in vitro PTB, but also completely inecient in recruiting Shc in living cells.
These results will allow in the near future to study more precisely the role of Shc activation in the context of the dierent biological eects, transformation and dierentiation, induced by the two Ret physiological isoforms and by its various pathological versions. The latter include RET/PTC oncogenes as well as the MEN2-associated RET-C634R and RET-M918T mutations which are all able to transform NIH3T3 cells Borrello et al., 1995) . Since the adaptor protein Shc is oncogenic by itself when overexpressed and is involved in T-antigen-mediated oncogenic transformation (Dilworth et al., 1993) , it will be of interest to study whether the dierent oncogenic forms of Ret carrying Y?F mutation at residue 1062, and thus completely unable to recruit Shc, are still able to transform NIH3T3 cells. The transforming ability of YF mutants should be analysed for either RET isoforms, since the long one alone is able to directly bind with high anity Grb2, whereas Grb2 binding to the short isoform could be Shc-mediated (manuscript in preparation). In addition, the present results will contribute to the analysis of the role of Shc in the physiological activation of proto-Ret receptor by the recently discovered GDNF ligand (Trupp et al., 1996; Durbec et al., 1996) .
Materials and methods

Site-directed mutagenesis and cloning of RET/PTC2 mutants
The cloning of the RET/PTC2 cDNA has been previously reported (Bongarzone et al., 1993) (EMBL data bank accession number L03357). The 2 kb XbaI cDNA insert was cloned into pAlter vector (Promega). Site-directed mutagenesis was performed using an in vitro oligonucleotide mutagenesis system (Altered Sites in vitro mutagenesis system from Promega). Oligonucleotide carrying the Tyr586?Phe was 5'-GAAAACAAACTCTTTGGTAGA-ATTTCCC-3', oligonucleotide carrying the Lys282?Arg was 5'-GGTGGCCGTGAGGATGCTGAAAGAG-3' synthesized with an Applied Biosystem 391 apparatus. The second mutation was screened for the creation of a new FokI restriction site; since the introduced mutation did not destroy nor create restriction sites for the ®rst mutation, mutant clones were identi®ed by Allele Speci®c Oligonucleotide (ASO) technique: a 193 bp fragment was ampli®ed by PCR around codon 586 and hybridized with the speci®c wt and mutated oligonucleotides 5'-AAACTCTATGG-CATGTCA-3' or 5'-AAACTCTTTGGCATGTCA-3' at stringent conditions to identify mutant clones. Full-length RET/PTC2 cDNA clones carrying the appropriate mutations were entirely sequenced. wt and mutant cDNAs were then inserted into the XbaI site of the eukaryotic expression vectors pRC-CMV (Invitrogen) under the control of the human cytomegalovirus (CMV) promoter.
Cell culture and transient transfection
COS7 and mouse NIH3T3 cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal calf serum and 10% calf serum, respectively. Before protein extraction, NIH3T3 cells and NIH3T3 derived cell lines were serum starved for 48 h in DMEM plus 0.1% bovine serum albumin (BSA) and 10 mM HEPES buer; in some cases, the cells were pretreated with 50 nM sodium orthovanadate (Na 3 VO 4 ) for 3 h.
For transient transfection COS7 cells were seeded at the density of 1610 6 cells/10 cm plate in complete medium and grown for 24 h prior to a 30' incubation in serum free medium with 500 mg/ml DEAE-destran, 1 mg/plate of speci®c DNA and 20 mg/plate of carrier plasmid DNA. After 30', the medium was removed and cells were incubated 3 h in complete medium plus 100 mM chloroquine. Cells were then grown in DMEM, 10% FCS, for 72 h before protein extraction.
Immunoprecipitation and Western blotting
Protein samples were prepared as previously reported and immunoprecipitated with the speci®ed antisera: anti-Ret common antiserum , anti-phosphotyrosine (anti-PTyr), a commercially available monoclonal IgG2b antiserum (Upstate Biotechnology Incorporated), anti-Shc monoclonal antibody (from PG Pelicci already described ) and a commercially available rabbit polyclonal antiShc (Upstate Biotechnology Incorporated). Dierent amounts of protein extracts were used, as speci®ed in the ®gures: for binding experiments 1 mg, for coimmunoprecipitation experiments about 3 ± 4 mg, for other immunoprecipitations experiments about 0.5 mg. Immunoprecipitates were resolved by electrophoresis on 7.5% or 8.5% SDSpolyacrylamide gels (PAGE). Proteins were transferred onto nitrocellulose ®lters, blocked with 5% bovine serum albumin (BSA) or 0.5% gelatin in Tris-buered saline (TBS) pH 7.6 and immunoblotted with the same anti-Ret antiserum described above or with another anity puri®ed anti-Ret common polyclonal antiserum both designated anti-Ret (3.5 mg ml 71 ), with anti-PTyr (0.2 mg ml 71 ) or anti-Shc antisera (1 mg ml 71 ). Immunoreactive bands were visualized using 125 I-labeled protein A (Amersham) followed by autoradiography or using a horseradish peroxidase conjugate anti-rabbit or anti-mouse antiserum and ECL detection reagents (Amersham). When 125 I-protein A was used, the ®lters were exposed to storage phosphor screen ®lms and analysed with PhosphorImager apparatus (Molecular Dynamics) in order to quantify the c.p.m. associated to the Ret-speci®c bands reacting with anti-Ret antisera.
In vitro immunocomplex kinase assay
The anti-Ret immunoprecipitates, absorbed on protein ASepharose beads, were washed twice with lysis buer, once with incubation buer (50 mM HEPES pH 7.2, 20 mM MnCl 2 , 5 mM PMSF) and incubated for 15 min at 48C in 20 ml of the same buer containing 0.5 mM DTT, 4 mCi of [g 32 P]ATP (5000 Ci mmol 71 , Amersham) diluted with unlabeled ATP to the ®nal concentration of 26 pmol ATP per sample and 50 mM of myelin basic protein (MBP). The reaction was stopped by addition of concentrated Laemmli buer. Proteins were eluted and subjected to 15% SDS ± PAGE.
32 P-labeled bands were revealed by autoradiography of the dried gel and analysed by PhosphorImager.
In vitro kinase assay using synthetic peptides In vitro kinase assay was performed as described in the previous paragraph with the following modi®cations: 250 mM of synthetic peptides instead of MBP were added, the reaction was carried out at 378C for 1 h and was stopped by adding 30% acetic acid. The peptides contained in the mixture of the immunokinase reaction were dried, resuspended in 25 ml water and separated by reverse phase HPLC on a Waters DELTA PAK 18C-300A Ê column, 15m, 7.8 mm6300 mm. Elution was performed at 1 ml min 71 with linear gradient from 15% to 85% solvent B in 30 min (solvent A was 0.05% tri¯uoroacetic acid in water/acetonitrile 95 : 5 and solvent B was 0.05% trifluoroacetic acid in water/acetonitrile 40 : 60). The eluant was monitored by a u.v. detector (Kontron Instruments) at 220 nm. The fractions were manually collected. The peptide-containing fractions (deduced by adding the synthetic cold phosphorylated reference peptide to the mixture, in a separate run) were dried, resuspended in 5 ml 30% acetic acid and spotted in 1 ml aliquots onto a 10620 cm 2 cellulose TLC plate (Merck). TLC plates were eluted with water/pyridine/acetic acid/1-butanol (60 : 50 : 75 : 15), air dried and exposed to X-ray ®lm (Hyper®lm-MP, Amersham). In addition, the same plate was stained with ninhydrin to reveal the reference peptides.
In vitro binding experiments using Gst-fused proteins and phosphopeptides competition
Bacterial cultures expressing pGEX vector alone (Pharmacia) or recombinant pGEX containing the SH2 or the PTB domain of Shc or that one of Grb2 were grown in LB containing 100 mg ml 71 ampicillin and induced with 1 mM isopropyl b-D-thiogalactopyranoside for 3 to 6 h. The induced bacteria were lysed by sonication in PBS containing 10 mg ml 71 of Aprotinin, Leupeptin and Pepstatin. Gst or Gst-fused proteins were puri®ed using glutathioneSepharose (Pharmacia) and retained in the immobilized form bound to glutathione-Sepharose. Cells were lysed as described . The clari®ed lysates were incubated with 5 ± 10 mg of immobilized Gst or Gst-fused proteins for 90 min at 48C. When indicated, 1% SDS was added and protein samples were treated 5' at 1008C and subsequently diluted to 0.1% SDS concentration, before the incubation with the Gst proteins. Protein complexes were resolved by SDS ± PAGE and transferred to nitrocellulose. Blots were blocked and probed as described above.
The peptide competition was performed by preincubating the Gst-fused proteins bound to the glutathione-Sepharose with the indicated concentration of peptides and phosphopeptides dissolved in PLC-LB buer, before adding the cell lysates. The phosphopeptides were synthesized as previously reported .
